IRVINE, CA--(Marketwired - May 19, 2015) - Truesdail Laboratories announced today it plans to appeal the termination of its contract with the Indiana Horse Racing Commission.

On May 12, 2015, the Indiana Horse Racing Commission notified Truesdail Laboratories it was terminating its contract with Truesdail. Another laboratory, acting under the Indiana Horse Racing Commission's QA audit program detected small amounts of two different drugs not found by Truesdail's screening protocols. The drugs, isoflupredone and betamethasone, were not detected in three samples that contained these drugs in amounts exceeding Indiana's medication rules.

"We are disappointed Indiana acted so abruptly," said Randy Gates of Truesdail Laboratories. "After the first notification from Indiana concerning this issue, Truesdail conducted an immediate and thorough root cause and corrective action investigation following the ISO/IEC 17025 accreditation guidelines. Additionally, the Company consulted with several university laboratories and reviewed literature for potential solutions to resolve this issue," he added.

"The root cause investigation identified a loss of sensitivity in the screening for the corticosteroid class of drug compounds," said Dr. Anthony Fontana of Truesdail Laboratories.

"Corrective actions were implemented within three days of notification and we are screening and confirming corticosteroid at RMTC and ARCI threshold levels. We have validated the results of our corrective actions by confirming replicate spiked serum samples at threshold levels," he added.

As a result of the corrective actions undertaken to resolve the issue of corticosteroid sensitivity, Truesdail is planning on appealing the termination within the 15 day contract cure period.

Founded in 1931, Truesdail Laboratories is committed to its motto of "Excellence in Independent Testing" and has taken every step to ensure that data of the highest quality is reported. It accreditations include: ISO/IEC 17025, RMTC ILAC G-7, ANSI ISO/IEC 17065, and CA ELAP. The company recently moved into a state-of-the-art testing laboratory and administrative facilities in Irvine, CA. The new 17,000 square foot facility was designed with current best lab practices to ensure quality data at the turn-around times our clients demand.

Contact Information:

Randy Gates
Chief Operating Officer
Truesdail Laboratories, Inc.